Phase I Study of a Combination of Fluvastatin and Celecoxib in Children with Relapsing/Refractory Low-Grade or High-Grade Glioma (FLUVABREX)
Authors:
- Pierre LeblondPLPierre Leblond
- Emmanuelle Tresch-BruneelETEmmanuelle Tresch-Bruneel
- Alicia ProbstAPAlicia Probst
- Nadège NéantNNNadège Néant
- Caroline SolasCSCaroline Solas
- Arthur SterinASArthur Sterin
- Thomas BoulangerTBThomas Boulanger
- Isabelle AertsIAIsabelle Aerts
- Cécile Faure-ConterCFCécile Faure-Conter
- Anne-Isabelle BertozziABAnne-Isabelle Bertozzi
- Pascal ChastagnerPCPascal Chastagner
- Natacha Entz-WerléNatacha Entz-Werlé
Open Access
Abstract
Preclinical data support the activity of celecoxib and fluvastatin in high-grade (HGG) and low-grade gliomas (LGG). A phase I trial (NCT02115074) was designed to evaluate the safety of this combination in children with refractory/relapsed HGG and LGG using four dose levels of fluvastatin with a fixed daily dose of celecoxib. A Continual Reassessment Method was used for fluvastatin dose escalation. Dose-limiting toxicities (DLT) were determined on the first treatment cycle. Twenty patients were included. Ten LGG and ten HGG patients received a median of 3.5 treatment cycles. Two DLTs were reported: one grade 3 maculopapular rash (4 mg/kg dose level) and one grade 4 increase of Creatine Phospho-Kinase (6 mg/kg dose level). We identified the dose of 6 mg/kg/day as the recommended phase II dose (RP2D) of fluvastatin with celecoxib. Four patients with LGG continued treatment beyond 12 cycles because of stable disease, including one patient who received 23 treatment cycles. In children with refractory/relapsed glioma, the RP2D of fluvastatin with celecoxib is 6 mg/kg/day. The long-term stable diseases observed in LGG suggest a possible role of the combination in a maintenance setting, given its good tolerance and low cost for children living in low- and middle-income countries.Keywords
Funding Information
- INCa PHRC-K (A29)
- Anticancer Fund (A29)
This publication has 47 references indexed in Scilit:
- Outcome analysis of childhood pilocytic astrocytomas: a retrospective study of 148 cases at a single institutionNeuropathology and Applied Neurobiology, 2013
- Evidence for new targets and synergistic effect of metronomic celecoxib/fluvastatin combination in pilocytic astrocytomaActa Neuropathologica Communications, 2013
- Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomasNature Genetics, 2013
- Long‐term efficacy and toxicity of bevacizumab‐based therapy in children with recurrent low‐grade gliomasPediatric Blood & Cancer, 2012
- Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: Toxicity and efficacy trendsPediatric Blood & Cancer, 2012
- Incidence of vasculopathy in children with hypothalamic/chiasmatic gliomas treated with brachytherapyChild's Nervous System, 2011
- CD36, a Scavenger Receptor Involved in Immunity, Metabolism, Angiogenesis, and BehaviorScience Signaling, 2009
- Pilocytic astrocytoma of the optic pathway: a tumour deriving from radial glia cells with a specific gene signatureBrain, 2009
- Cognitive and Adaptive Outcome in Extracerebellar Low-Grade Brain Tumors in Children: A Report From the Children's Oncology GroupJournal of Clinical Oncology, 2008
- Phase II Study of Metronomic Chemotherapy with Thalidomide, Carboplatin-Vincristine-Fluvastatin in the Treatment of Brain Stem Tumors in ChildrenArchives of Medical Research, 2008